Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA and Health Care Reform: An Activist Agenda for the Agency

This article was originally published in RPM Report

Executive Summary

Everyone is gearing up for a debate over health care reform in 2009-including the Food & Drug Administration. The regulator's role may be bigger than you think.

You may also be interested in...



Margaret Hamburg: The Public Health Commissioner

An interview with newly confirmed FDA Commissioner Margaret Hamburg.

Commissioner Nominee Hamburg Questioned On FDA’s Role In Health Reform

Congressional questioning during the confirmation hearing of FDA Commissioner-designate Margaret Hamburg May 7 underscored the influence the probable agency chief would have in an era of health care reform

Commissioner Nominee Hamburg Questioned On FDA’s Role In Health Reform

Congressional questioning during the confirmation hearing of FDA Commissioner-designate Margaret Hamburg May 7 underscored the influence the probable agency chief would have in an era of health care reform

Related Content

Topics

UsernamePublicRestriction

Register

PS080383

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel